Ventures Acacia Pharma 7. oktober 2020 Acacia Pharma Group PLC – Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the US Acacia Pharma 1. oktober 2020 Acacia Pharma Group PLC – PDMR Dealing/Issue of Equity Enterome 23. september 2020 Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease Auro Biosciences 11. september 2020 Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma Enterome 9. september 2020 Enterome – First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative ‘OncoMimic’ based Immunotherapy Candidate Targeting Adrenal Tumors Spero Therapeutics 8. september 2020 Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis Acacia Pharma 24. august 2020 Acacia Pharma’s BARHEMSYS® (amisulpride injection) Launched and Commercially Available in the US for the Treatment and Prevention of Postoperative Nausea & Vomiting (PONV) Bonesupport 21. august 2020 BONESUPPORT HOLDING AB (publ) announces that the patient enrolment schedule for the ongoing FORTIFY study is extended Acacia Pharma 18. august 2020 Acacia Pharma Group plc Admission to Trading on Euronext Brussels Amplyx Pharmaceuticals 18. august 2020 Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients Sideinddeling Første side « Første Forrige side ‹‹ Side 1 Nuværende side 2 Side 3 Side 4 Side 5 Side 6 Side 7 Side 8 Side 9 … Næste side ›› Sidste side Sidste »
